Bolognesi_2005_Farmaco_60_465

Reference

Title : Heterocyclic inhibitors of AChE acylation and peripheral sites - Bolognesi_2005_Farmaco_60_465
Author(s) : Bolognesi ML , Andrisano V , Bartolini M , Cavalli A , Minarini A , Recanatini M , Rosini M , Tumiatti V , Melchiorre C
Ref : Farmaco , 60 :465 , 2005
Abstract : Notwithstanding the criticism to the so called " cholinergic hypothesis", the therapeutic strategies for the treatment of Alzheimer's disease (AD) have been mainly centered on the restoration of cholinergic functionality and, until the last year, the only drugs licensed for the management of AD were the acetycholinesterase (AChE) inhibitors. Target enzyme AChE consists of a narrow gorge with two separate ligand binding sites: an acylation site at the bottom of the gorge containing the catalytic triad and a peripheral site located at the gorge rim, which encompasses binding sites for allosteric ligands. The aim of this short review is to update the knowledge on heterocyclic AChE inhibitors able to interact with the two sites of enzymes, structurally related to the well known inhibitors physostigmine, rivastigmine and propidium. The therapeutic potential of the dual site inhibithors in inhibiting amyloid-beta aggregatrion and deposition is also briefly summarised.
ESTHER : Bolognesi_2005_Farmaco_60_465
PubMedSearch : Bolognesi_2005_Farmaco_60_465
PubMedID: 15878569

Related information

Citations formats

Bolognesi ML, Andrisano V, Bartolini M, Cavalli A, Minarini A, Recanatini M, Rosini M, Tumiatti V, Melchiorre C (2005)
Heterocyclic inhibitors of AChE acylation and peripheral sites
Farmaco 60 :465

Bolognesi ML, Andrisano V, Bartolini M, Cavalli A, Minarini A, Recanatini M, Rosini M, Tumiatti V, Melchiorre C (2005)
Farmaco 60 :465